Overall Survival

Keytruda as a Second Line Treatment for Mesothelioma

A new second line treatment has been developed for pleural mesothelioma. The treatment was created at the Netherlands Cancer Institute in Amsterdam. Research was done as a single-arm, open-label clinical trial combining pembrolizumab (Keytruda) and lenvatinib. The results were presented at the IASCL 2022 World Conference on Lung Cancer in[…]

Read More »

A New Blood Test That Can Diagnose Mesothelioma Has Been Developed

A blood test could make diagnosing mesothelioma faster, leading to doctors catching the disease earlier in patients. Mesothelioma is a hard-to-treat cancer mainly caused by asbestos. Once diagnosed, not much can be done because it has usually spread and progressed to a point where treatments like surgery, chemotherapy, and radiation[…]

Read More »

Researchers Found a Relationship Between GISTs and Peritoneal Mesothelioma

Scientists may have found an easy way to identify peritoneal mesothelioma, making it easier to detect and catch the cancer earlier. These researchers may have found a link between peritoneal mesothelioma and gastrointestinal stromal tumors. The research done in the division of surgical oncology at University of California San Diego[…]

Read More »

SMARTEST Trial Hopes to Improve Survival Times for Mesothelioma

Researchers are performing a clinical trial hoping that they can make pleural mesothelioma a more manageable, and even survivable, disease. The clinical trial is being done at Princess Margaret Cancer Center in Toronto. The trial is known as SMARTEST, which stands for Surgery for Mesothelioma After Radiation Therapy using Exquisite[…]

Read More »

Galinpepimut-S Cancer Vaccine in Combination with Opdivo

Promising results from a study on pleural mesothelioma were recently released. The study found when patients were treated with a new combination treatment, patients lived longer and had a better quality of life. The phase I clinical trial utilized a targeted cancer vaccine known as galinpepimut-S (GPS) and the immunotherapy[…]

Read More »

Increasing Levels of Women are Dying from Mesothelioma

Over the past 20 years, the number of women dying from mesothelioma increased by 25 percent. This is happening even with less asbestos being used. Deaths in men have been falling, the reverse of what is happening in women. The information was published in the Morbidity and Mortality Weekly Report[…]

Read More »

Targeted Therapy is Showing Promising Results for Mesothelioma

Targeted research is advancing the treatment of pleural mesothelioma. Results from a study on a novel protein inhibitor known as tazemetostat (brand name Tazverik) were recently released. It is showing impressive results as a second line treatment for mesothelioma patients with the BAP1 genetic mutation. The control rate for disease[…]

Read More »

Vudalimab for the Treatment of Mesothelioma

The MD Anderson Cancer Center is conducting a study on an immunotherapy drug that is specifically for rare, advanced tumors. Pleural and peritoneal mesothelioma are both included in the study. The clinical trial is looking for effectiveness and safety of vudalimab. The treatment, also known as XmAb20717, was created by[…]

Read More »

Proton Beam Radiation Therapy Use Increases for Mesothelioma and Lung Cancer

Proton beam radiation therapy is growing in popularity for treating mesothelioma and lung cancer. A study in JAMA Oncology looked at the use of this radiation for treating different types of cancer. There were almost 6 million patients in the study and data shows that proton radiation use tripled from[…]

Read More »

Monoclonal Antibody Treatment was Found Not to be Effective on Pleural Mesothelioma

A phase II clinical trial comparing anetumab ravtansine to the chemotherapy drug vinorelbine did not have promising results for treating mesothelioma like researchers had hoped. Anetumab ravtansine is an immunotherapy drug that is a monoclonal antibody, which is an engineered antibody that can be used to fight cancer. Researchers found[…]

Read More »